A recent report from a global point of view has pointed out that EGFR mutation–positive NSCLC patients have relatively lower glycolysis compared with NSCLC patients without EGFR mutation (SUVmax 7.0 ± 3.9 vs. 10.3 ± 5.8) [33]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.